- Home
- RYTM
as 07-26-2024 4:00pm EST
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
Upcoming Earnings Alert:
Get ready for potential market movements as Rhythm Pharmaceuticals Inc. RYTM prepares to release earnings report on 30 Jul 2024.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 2.2B | IPO Year: | 2017 |
| Target Price: | $55.83 | AVG Volume (30 days): | 498.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.65 - $53.92 | Next Earning Date: | 07-30-2024 |
| Revenue: | $91,926,000 | Revenue Growth: | 173.52% |
| Revenue Growth (this year): | 62.5% | Revenue Growth (next year): | 50.77% |
Stock Insider Trading Activity of Rhythm Pharmaceuticals Inc. (RYTM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Shulman Joseph | RYTM | Chief Technical Officer | Jul 16 '24 | Sell | $53.00 | 10,468 | $554,816.56 | 30 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Jul 12 '24 | Sell | $50.01 | 5,313 | $265,724.91 | 30 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | May 9 '24 | Sell | $39.10 | 500 | $19,551.00 | 30 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | May 9 '24 | Sell | $38.38 | 3,484 | $133,707.56 | 530 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Mar 21 '24 | Sell | $40.34 | 18,235 | $735,599.90 | 30 | SEC Form 4 |
| German Christopher Paul | RYTM | Corporate Controller & CAO | Mar 20 '24 | Sell | $41.76 | 368 | $15,367.68 | 795 | SEC Form 4 |
| Lee Jennifer Kayden | RYTM | EVP, Head of North America | Mar 20 '24 | Sell | $38.22 | 9,169 | $350,439.18 | 15,918 | SEC Form 4 |
| Lee Jennifer Kayden | RYTM | EVP, Head of North America | Mar 20 '24 | Sell | $39.33 | 9,066 | $356,565.78 | 6,852 | SEC Form 4 |
| Meeker David P | RYTM | President and CEO | Mar 19 '24 | Sell | $39.22 | 45,494 | $1,784,274.68 | 174,605 | SEC Form 4 |
| Lee Jennifer Kayden | RYTM | EVP, Head of North America | Mar 19 '24 | Sell | $39.22 | 15,515 | $608,498.30 | 25,087 | SEC Form 4 |
| Smith Hunter C | RYTM | Chief Financial Officer | Mar 19 '24 | Sell | $39.22 | 15,515 | $608,498.30 | 97,939 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Mar 19 '24 | Sell | $39.22 | 15,515 | $608,498.30 | 18,265 | SEC Form 4 |
| Mazabraud Yann | RYTM | EVP, Head of International | Mar 19 '24 | Sell | $39.22 | 16,000 | $627,520.00 | 24,495 | SEC Form 4 |
| Cramer Pamela J. | RYTM | Chief Human Resources Officer | Mar 19 '24 | Sell | $39.22 | 15,515 | $608,498.30 | 30,005 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Feb 13 '24 | Sell | $50.01 | 1,089 | $54,460.89 | 30 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Feb 13 '24 | Sell | $50.00 | 1,865 | $93,250.00 | 1,119 | SEC Form 4 |
| Smith Hunter C | RYTM | Chief Financial Officer | Feb 9 '24 | Sell | $51.38 | 1,209 | $62,118.42 | 80,413 | SEC Form 4 |
| Smith Hunter C | RYTM | Chief Financial Officer | Feb 9 '24 | Sell | $49.82 | 709 | $35,322.38 | 79,704 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Feb 9 '24 | Sell | $48.24 | 100 | $4,824.00 | 74,360 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Feb 9 '24 | Sell | $50.14 | 48,177 | $2,415,503.24 | 26,183 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Feb 9 '24 | Sell | $50.88 | 23,397 | $1,190,502.53 | 2,786 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Feb 9 '24 | Sell | $51.52 | 100 | $5,152.00 | 2,686 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Feb 9 '24 | Sell | $51.38 | 791 | $40,641.58 | 3,457 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Feb 9 '24 | Sell | $49.84 | 473 | $23,574.32 | 2,984 | SEC Form 4 |
| Mazabraud Yann | RYTM | EVP, Head of International | Feb 9 '24 | Sell | $51.38 | 1,594 | $81,899.72 | 7,702 | SEC Form 4 |
Latest Rhythm Pharmaceuticals Inc. News
RYTM Breaking Stock News: Dive into RYTM Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Needham Adjusts Price Target on Rhythm Pharmaceuticals to $55 From $46, Maintains Buy Rating
MT Newswires
3 days ago
Rhythm Pharmaceuticals Doses First Patients in Trial of Hypothalamic Obesity Treatment
GlobeNewswire
4 days ago
Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity
GlobeNewswire
4 days ago
Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
MT Newswires
8 days ago
Rhythm Pharmaceuticals Insider Sold Shares Worth $554,817, According to a Recent SEC Filing
GlobeNewswire
15 days ago
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
MT Newswires
18 days ago
Rhythm Pharmaceuticals Appoints Alastair Garfield as Chief Scientific Officer
GlobeNewswire
19 days ago
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
Compare RYTM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RYTM Rhythm Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.